Banner
targets (3)
for drugs
Identification
Name Uridine Diphosphate Galactose
Accession Number DB03501 (EXPT01576)
Type small molecule
Groups experimental
Description

A nucleoside diphosphate sugar which can be epimerized into UDPglucose for entry into the mainstream of carbohydrate metabolism. Serves as a source of galactose in the synthesis of lipopolysaccharides, cerebrosides, and lactose. [PubChem]
Structure Thumb
Download: MOL | SDF | SMILES | InChI
Display: 2D Structure | 3D Structure
Synonyms
GALACTOSE-URIDINE-5'-DIPHOSPHATE
GDU
UDP galactose
UDP-alpha-d-galactose
UDP-D-Galactopyranose
UDP-d-galactose
UDP-gal
UDP-galactopyranose
UDP-galactose
UDPgal
UPG
Uridine 5'-diphosphate galactose
Uridine 5'-diphosphogalactose
Uridine diphosphate-d-galactose
Uridine diphosphogalactose
Uridine pyrophosphogalactose
Uridinediphosphate galactose
Uridinediphosphogalactose
First Prev Next Last
Salts Not Available
Brand names Not Available
Brand mixtures Not Available
Categories Not Available
CAS number 2956-16-3
Weight Average: 566.3018
Monoisotopic: 566.055020376
Chemical Formula C15H24N2O17P2
InChI Key InChIKey=HSCJRCZFDFQWRP-LJMZODOWSA-N
InChI
InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8-,9-,10+,11+,12-,13+,14+/m0/s1
Plain Text
IUPAC Name
[({[(2S,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphinic acid
SMILES
OC[C@@H]1O[C@H](O[P@](O)(=O)O[P@@](O)(=O)OC[C@@H]2O[C@H]([C@H](O)[C@H]2O)N2C=CC(=O)NC2=O)[C@@H](O)[C@H](O)[C@H]1O
Plain Text
Mass Spec Not Available
Taxonomy
Kingdom Not Available
Classes Not Available
Substructures Not Available
Pharmacology
Indication Not Available
Pharmacodynamics Not Available
Mechanism of action Not Available
Absorption Not Available
Volume of distribution Not Available
Protein binding Not Available
Metabolism Not Available
Route of elimination Not Available
Half life Not Available
Clearance Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Pathways Not Available
Pharmacoeconomics
Manufacturers Not Available
Packagers Not Available
Dosage forms Not Available
Prices Not Available
Patents Not Available
Properties
State solid
Experimental Properties Not Available
Predicted Properties
Property Value Source
water solubility 1.50e+01 g/l ALOGPS
logP -1.4 ALOGPS
logP -5 ChemAxon
logS -1.6 ALOGPS
pKa (strongest acidic) 1.73 ChemAxon
pKa (strongest basic) -3.6 ChemAxon
physiological charge -2 ChemAxon
hydrogen acceptor count 14 ChemAxon
hydrogen donor count 9 ChemAxon
polar surface area 291.54 ChemAxon
rotatable bond count 9 ChemAxon
refractivity 106.46 ChemAxon
polarizability 46.81 ChemAxon
References
Synthesis Reference Not Available
General Reference Not Available
External Links
Resource Link
KEGG Compound C00052 Link_out
PubChem Compound 46936243 Link_out
PubChem Substance 46507114 Link_out
ChEBI 18307 Link_out
ChEMBL 18307 Link_out
HET GDU Link_out
ATC Codes Not Available
AHFS Codes Not Available
PDB Entries
FDA label Not Available
MSDS Not Available
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Targets

1. Beta-1,4-galactosyltransferase 1

Pharmacological action: unknown

The cell surface form functions as a recognition molecule during a variety of cell to cell and cell to matrix interactions, as those occurring during development and egg fertilization, by binding to specific oligosaccharide ligands on opposing cells or in the extracellular matrix

Organism class: human
UniProt ID: P15291 Link_out
Gene: B4GALT1 Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Ramakrishnan B, Balaji PV, Qasba PK: Crystal structure of beta1,4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site. J Mol Biol. 2002 Apr 26;318(2):491-502. Pubmed
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

2. Histo-blood group ABO system transferase

Pharmacological action: unknown

This protein is the basis of the ABO blood group system. The histo-blood group ABO involves three carbohydrate antigens:A, B, and H. A, B, and AB individuals express a glycosyltransferase activity that converts the H antigen to the A antigen (by addition of UDP-GalNAc) or to the B antigen (by addition of UDP-Gal), whereas O individuals lack such activity

Organism class: human
UniProt ID: P16442 Link_out
Gene: ABO Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Nguyen HP, Seto NO, Cai Y, Leinala EK, Borisova SN, Palcic MM, Evans SV: The influence of an intramolecular hydrogen bond in differential recognition of inhibitory acceptor analogs by human ABO blood group A and B glycosyltransferases. J Biol Chem. 2003 Dec 5;278(49):49191-5. Epub 2003 Sep 11. Pubmed

3. UDP-glucose 4-epimerase

Pharmacological action: unknown

Catalyzes two distinct but analogous reactions:the epimerization of UDP-glucose to UDP-galactose and the epimerization of UDP-N-acetylglucosamine to UDP-N- acetylgalactosamine

Organism class: human
UniProt ID: Q14376 Link_out
Gene: GALE Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM: Molecular basis for severe epimerase deficiency galactosemia. X-ray structure of the human V94m-substituted UDP-galactose 4-epimerase. J Biol Chem. 2001 Jun 8;276(23):20617-23. Epub 2001 Mar 7. Pubmed
Comments
Drug created on June 13, 2005 07:24 / Updated on February 08, 2013 16:22